Dapagliflozin is well studied in type 2 diabetes mellitus and HF and CKD patients with positive results and a good safety profile.
Read More »Canagliflozin vs. Sotagliflozin for Stroke Prevention in Patients with T2D and CKD
SGLT2 inhibitors are not created equal; patient-specific characteristics need to be considered for best efficacy.
Read More »57th EASD: Sotagliflozin for Type 2 Diabetes
While it does not yet have FDA approval, researchers find novel dual SGLT-1/2 inhibitor, sotagliflozin, is efficacious and safe for patients with type 2 diabetes.
Read More »Canagliflozin’s Renal and Cardiovascular Benefits in People with Heart Failure
CREDENCE trial shows that canagliflozin, an SGLT2 inhibitor, lowers the risk of cardiovascular and renal events in patients with T2DM, regardless of prior history of heart failure.
Read More »Canagliflozin Reduces Hospitalizations
Canagliflozin, an SGLT2 inhibitor, and its impact in reducing hospitalizations and health care costs in people with type 2 diabetes.
Read More »Mortality and Cardiovascular Benefits of SGLT-2 Inhibitors in Type 2 Diabetes
Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?
Read More »Empagliflozin Receives Breakthrough Therapy Designation for HFpEF
The FDA has approved empagliflozin Breakthrough therapy for patients with heart failure with preserved ejection fraction (HFpEF).
Read More »Using Dapagliflozin for Reduction in Adverse Renal and CV Outcomes
Patients had significant reduction in urinary albumin-to-creatinine ratio (UACR) in the first six months of using dapagliflozin.
Read More »SGLT-2 vs. Sulfonylureas
The most common treatment for T2D has been the metformin-sulfonylurea combo; how do SGLT-2 inhibitors compare in all-cause mortality risk?
Read More »GLP-1 vs. SGLT-2 in Geriatric Patients
Researchers compare the cardiovascular effectiveness and safety of GLP-1 agonists and SGLT-2 inhibitors in older adults.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.